Myriad Genetics (MYGN) Chief Scientific Officer gets 23,697 PSUs

Rhea-AI Filing Summary

Myriad Genetics reported that its Chief Scientific Officer, Dale Muzzey, received an award of 23,697 shares of common stock on February 2, 2026, at a price of $0 per share, increasing his directly held stake to 193,878 shares.

The shares relate to performance-based restricted stock units initially granted on March 15, 2023. The board’s Compensation and Human Capital Committee determined the final award amount based on pre-set performance metrics, and each unit will convert into one share of common stock vesting on March 15, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Muzzey Dale

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	23,697	$0.00	--

Holdings After Transaction: Common Stock — 193,878 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muzzey Dale

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		23,697(1)	A	$0	193,878	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026.

Remarks:

	By: Justin Hunter For: Dale Muzzey	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Myriad Genetics (MYGN) disclose for February 2, 2026?

Myriad Genetics disclosed that Chief Scientific Officer Dale Muzzey received 23,697 shares of common stock on February 2, 2026. The award came at a price of $0 per share as part of performance-based restricted stock units tied to earlier-set performance metrics.

Who is the insider in the latest Myriad Genetics (MYGN) Form 4 filing?

The insider is Dale Muzzey, Chief Scientific Officer of Myriad Genetics. The filing shows he now directly holds 193,878 shares of common stock following the February 2, 2026 award related to previously granted performance-based restricted stock units.

How many Myriad Genetics (MYGN) shares did the Chief Scientific Officer acquire?

The Chief Scientific Officer acquired 23,697 shares of Myriad Genetics common stock. These shares stem from performance-based restricted stock units whose final amount was set by the board’s Compensation and Human Capital Committee based on achievement of predetermined performance metrics.

What are the terms of the performance-based restricted stock units in Myriad Genetics (MYGN) Form 4?

The performance-based restricted stock units were initially granted on March 15, 2023. Each unit represents a contingent right to receive one share of common stock and vests on March 15, 2026, after the Compensation and Human Capital Committee determined the final award based on performance metrics.

When do the reported Myriad Genetics (MYGN) PSUs vest for the Chief Scientific Officer?

The performance-based restricted stock units vest on March 15, 2026. At vesting, each PSU converts into one share of Myriad Genetics common stock, reflecting the final award amount set after evaluating achievement of the applicable performance metrics on February 2, 2026.

How many Myriad Genetics (MYGN) shares does the Chief Scientific Officer own after the transaction?

After the reported transaction, the Chief Scientific Officer beneficially owns 193,878 shares of Myriad Genetics common stock directly. This total includes the 23,697 shares associated with performance-based restricted stock units determined by the board committee based on preset performance criteria.